Cellectis SA (NASDAQ:CLLS) Expected to Announce Quarterly Sales of $1.40 Million

Wall Street brokerages forecast that Cellectis SA (NASDAQ:CLLS) will announce $1.40 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Cellectis’ earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $2.29 million. Cellectis posted sales of $2.19 million during the same quarter last year, which suggests a negative year-over-year growth rate of 36.1%. The business is scheduled to announce its next earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Cellectis will report full year sales of $12.74 million for the current fiscal year, with estimates ranging from $10.14 million to $14.40 million. For the next financial year, analysts anticipate that the company will post sales of $51.80 million, with estimates ranging from $15.00 million to $85.20 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Cellectis.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.18). Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%. The business had revenue of $2.93 million for the quarter, compared to the consensus estimate of $3.45 million.

Several equities research analysts recently commented on the stock. Zacks Investment Research raised shares of Cellectis from a “sell” rating to a “hold” rating in a research note on Monday, August 26th. BTIG Research assumed coverage on shares of Cellectis in a research note on Friday, August 9th. They set a “buy” rating and a $37.00 price objective on the stock. BidaskClub lowered shares of Cellectis from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 17th. Goldman Sachs Group set a $20.00 price objective on shares of Cellectis and gave the stock a “hold” rating in a research note on Monday, August 12th. Finally, ValuEngine raised shares of Cellectis from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $31.67.

NASDAQ:CLLS opened at $10.75 on Friday. Cellectis has a one year low of $9.50 and a one year high of $27.15. The company has a debt-to-equity ratio of 0.11, a current ratio of 8.47 and a quick ratio of 8.46. The company’s 50-day simple moving average is $11.00 and its 200 day simple moving average is $14.89. The firm has a market capitalization of $448.70 million, a P/E ratio of -5.57 and a beta of 1.74.

A number of institutional investors have recently modified their holdings of CLLS. Cubist Systematic Strategies LLC purchased a new position in Cellectis in the second quarter worth about $103,000. Aperio Group LLC purchased a new position in Cellectis in the second quarter worth about $147,000. A.R.T. Advisors LLC purchased a new position in Cellectis in the second quarter worth about $171,000. OneAscent Financial Services LLC purchased a new position in Cellectis in the second quarter worth about $257,000. Finally, D. E. Shaw & Co. Inc. purchased a new position in Cellectis in the second quarter worth about $502,000. 31.65% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Read More: What is channel trading?

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.